SSA
PTGX icon

Schonfeld Strategic Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-95,190
Closed -$6.32M – 2490
2025
Q3 		$6.32M Buy
95,190
+18,122
+24% +$1.03M 0.04% 505
2025
Q2 		$4.26M Sell
77,068
-210,233
-73% -$10.1M 0.03% 617
2025
Q1 		$13.9M Buy
+287,301
New +$12M 0.08% 237
2024
Q4 		– Sell
-61,026
Closed -$2.75M – 2314
2024
Q3 		$2.75M Buy
61,026
+11,962
+24% +$483K 0.02% 757
2024
Q2 		$1.7M Buy
+49,064
New +$1.44M 0.01% 975
2024
Q1 		– Sell
-89,113
Closed -$2.04M – 2333
2023
Q4 		$2.04M Sell
89,113
-64,985
-42% -$1.14M 0.01% 790
2023
Q3 		$2.57M Buy
+154,098
New +$2.99M 0.02% 744
2023
Q2 		– Sell
-148,992
Closed -$3.43M – 2432
2023
Q1 		$3.43M Buy
+148,992
New +$2.5M 0.03% 543
2022
Q4 		– Sell
-31,814
Closed -$268K – 2927
2022
Q3 		$268K Sell
31,814
-16,218
-34% -$153K ﹤0.01% 2156
2022
Q2 		$380K Buy
48,032
+34,332
+251% +$415K ﹤0.01% 1527
2022
Q1 		$325K Buy
+13,700
New +$386K ﹤0.01% 1645
2021
Q3 		– Sell
-5,000
Closed -$224K – 2406
2021
Q2 		$224K Buy
+5,000
New +$165K ﹤0.01% 1613
2019
Q3 		– Sell
-101,800
Closed -$1.23M – 1194
2019
Q2 		$1.23M Buy
101,800
+77,800
+324% +$860K 0.04% 390
2019
Q1 		$301K Buy
+24,000
New +$212K 0.01% 833

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Schonfeld Strategic Advisors's PTGX Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 95,190 shares — an estimated $6.32M sold.

Schonfeld Strategic Advisors first reported a position in PTGX in Q1 2019 and held it in 14 quarters. The position peaked at $13.9M in Q1 2025. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 95,190 Protagonist Therapeutics shares in Q4 2025, an estimated $6.32M.
  • Schonfeld Strategic Advisors first reported a position in Protagonist Therapeutics in Q1 2019 and held it in 14 quarters.
  • Schonfeld Strategic Advisors's Protagonist Therapeutics position peaked at $13.9M in Q1 2025.
  • 313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.